{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=30", "query": { "intervention": "dose level 1", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 29101, "total_pages": 2911, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T08:12:50.715Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03611868", "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable or Metastatic Melanoma or Advanced Solid Tumors", "Melanoma", "Uveal Melanoma", "P53 Mutation", "MDM2 Gene Mutation", "Cutaneous Melanoma", "Mucosal Melanoma", "Malignant Peripheral Nerve Sheath Tumors (MPNST)" ], "interventions": [ { "name": "Phase 1b: APG-115+pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 230, "start_date": "2018-08-29", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 17, "location_summary": "Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03611868" }, { "nct_id": "NCT07162363", "title": "Synergistic Minimally Invasive Surgery and Deferoxamine in ICH", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Intracerebral Hemorrhage", "ICH - Intracerebral Hemorrhage" ], "interventions": [ { "name": "Minimally Invasive surgery (MIS)", "type": "PROCEDURE" }, { "name": "Deferoxamine", "type": "DRUG" }, { "name": "Standard Medical Care (SMD)", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "University of Illinois Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 240, "start_date": "2026-03-01", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07162363" }, { "nct_id": "NCT03731221", "title": "Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Video Assisted Thoracic Surgery" ], "interventions": [ { "name": "Bupi HCI and lipo bupi", "type": "DRUG" }, { "name": "Bupi HCI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 196, "start_date": "2018-11-01", "completion_date": "2024-09-19", "has_results": false, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03731221" }, { "nct_id": "NCT00363714", "title": "A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "AGN211745", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 26, "start_date": "2004-11", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2008-08-18", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Cleveland, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363714" }, { "nct_id": "NCT03020784", "title": "Safety and Tolerability of PF-06818883 in Healthy Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-06818883", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2016-11-11", "completion_date": "2017-06-13", "has_results": false, "last_update_posted_date": "2017-12-11", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03020784" }, { "nct_id": "NCT07911033", "title": "Relationship Between Insulin Dose and Complications in Type 1 Diabetes", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus, Type 1 Diabetes", "Cardiovascular Diseases (CVD)", "Severe Albuminuria", "Estimated Glomerular Filtration Rate (eGFR)", "Hypoglycemia (Diabetic)", "Vascular Calcification", "Carotid-femoral Pulse Wave Velocity", "Kidney Diseases" ], "interventions": [ { "name": "Routine/prescribed exogenous insulin dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rachel Miller", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 80, "start_date": "2027-01", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07911033" }, { "nct_id": "NCT04234048", "title": "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphoma", "Cutaneous/Peripheral T-Cell Lymphoma", "Peripheral T-cell Lymphoma", "Peripheral T-Cell Lymphoma, Not Classified", "Primary Cutaneous T-cell Lymphoma", "Cutaneous T-Cell Lymphoma, Unspecified", "Cutaneous T-cell Lymphoma", "Follicular T-Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Sézary's Disease", "Mycosis Fungoides" ], "interventions": [ { "name": "Fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciTech Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-12-18", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234048" }, { "nct_id": "NCT02401048", "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2015-05", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401048" }, { "nct_id": "NCT02765555", "title": "First in Man Study of Safety, Tolerability and PK Profile of RBP-7000", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "RBP-7000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indivior Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "ALL", "summary": "18 Years to 42 Years" }, "enrollment_count": 12, "start_date": "2010-03", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2016-05-06", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 1, "location_summary": "Willingboro, New Jersey", "locations": [ { "city": "Willingboro", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02765555" }, { "nct_id": "NCT05013255", "title": "Pioglitazone Therapy Targeting Fatigue in Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Muscle Fatigue" ], "interventions": [ { "name": "Pioglitazone 15mg", "type": "DRUG" }, { "name": "Pioglitazone 30 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2021-12-23", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-11-15T08:12:50.715Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013255" } ] }